参考文献/References:
[1] Savarese G,Lund LH. Global public health burden of heart failure[J]. Card Fail Rev,2017,3(1):7-11.
[2] 徐俊波,黄刚,蔡琳,等. 2019 ESC-HFA射血分数保留性心力衰竭诊断共识的解读[J]. 心血管病学进展,2019,40(9):1193-1195.
[3] Rose EA,Gelijns AC,Moskowitz AJ,et al. Long-term use of a left ventricular assist device for end-stage heart failure[J]. N Engl J Med,2001,345(20):1435-1443.
[4] Slaughter MS,Rogers JG,Milano CA,et al. Advanced heart failure treated with continuous-flow left ventricular assist device[J]. N Engl J Med,2009,361(23):2241-2251.
[5] Kormos RL,Cowger J,Pagani FD,et al. The Society of Thoracic Surgeons Intermacs database annual report:evolving indications,outcomes,and scientific partnerships[J]. Ann Thorac Surg,2019,107(2):341-353.
[6] Adams EE,Wrightson ML. Quality of life with an LVAD:a misunderstood concept[J]. Heart Lung,2018,47(3):177-183.
[7] Warraich HJ,Allen LA,Blue LJ,et al. Comorbidities and the decision to undergo or forego destination therapy left ventricular assist device implantation:an analysis from the Trial of a Shared Decision Support Intervention for Patients and their Caregivers Offered Destination Therapy for End-Stage Heart Failure (DECIDE-LVAD) study[J]. Am Heart J,2019,213:91-96.
[8] Vorovich E. The mechanical revolution[J]. J Card Fail,2018,24(5):335-336.
[9] Yancy CW,Jessup M,Bozkurt B,et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation,2017,136(6):e137-e161.
[10] Yancy CW,Jessup M,Bozkurt B,et al. 2013 ACCF/AHA guideline for the management of heart failure:executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Circulation,2013,128(16):1810-1852.
[11] Miller LW,Pagani FD,Russell SD ,et al. Use of a continuous-flow device in patients awaiting heart transplantation[Z]. N Engl J Med,2007,357(9):885-896.
[12] Kirklin JK,Naftel DC,Kormos RL,et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate Ⅱ left ventricular assist device[J]. J Heart Lung Transplant,2014,33(1):12-22.
[13] Starling RC,Moazami N,Silvestry SC,et al. Unexpected abrupt increase in left ventricular assist device thrombosis[J]. N Engl J Med,2014,370(1):33-40.
[14] Maltais S,Kilic A,Nathan S,et al. PREVENtion of heartmate Ⅱ pump thrombosis through clinical management:the PREVENT multi-center study[J]. J Heart Lung Transplant,2017,36(1):1-12.
[15] Mehra MR,Uriel N,Naka Y,et al. A fully magnetically levitated left ventricular assist device—Final report[J]. N Engl J Med,2019,380(17):1618-1627.
[16] Schroder JN,Milano CA. A tale of two centrifugal left ventricular assist devices[J]. J Thorac Cardiovasc Surg,2017,154(3):850-852.
[17] Rogers JG,Pagani FD,Tatooles AJ,et al. Intrapericardial left ventricular assist device for advanced heart failure[J]. N Engl J Med,2017,376(5):451-460.
[18] Teuteberg JJ,Slaughter MS,Rogers JG,et al. The HVAD left ventricular assist device:risk factors for neurological events and risk mitigation strategies[J]. JACC Heart Fail,2015,3(10):818-828.
[19] Milano CA,Rogers JG,Tatooles AJ,et al. HVAD:the ENDURANCE supplemental trial[J]. JACC Heart Fail,2018,6(9):792-802.
[20] Colombo PC,Mehra MR,Goldstein DJ,et al. Comprehensive analysis of stroke in the long-term cohort of the MOMENTUM 3 study[J]. Circulation,2019,139(2):155-168.
[21] Thenappan T,Stulak JM,Agarwal R,et al. Early intervention for lactate dehydrogenase elevation improves clinical outcomes in patients with the HeartMate Ⅱ left ventricular assist device:insights from the PREVENT study[J]. J Heart Lung Transplant,2018,37(1):25-32.
[22] Zuin M,Rigatelli G,Braggion G,et al. Cavitation in left ventricular assist device patients:a potential early sign of pump thrombosis[J]. Heart Fail Rev,201 9,Nov 5. DOI:10.1007/S10741-019-09884-0.
[23] Upshaw JN,Kiernan MS,Morine KJ,et al. Incidence,management,and outcome of suspected continuous-flow left ventricular assist device thrombosis[J]. ASAIO J,2016,62(1):33-39.
[24] Muthiah K,Robson D,Macdonald PS,et al. Thrombolysis for suspected intrapump thrombosis in patients with continuous flow centrifugal left ventricular assist device[J]. Artif Organs,2013,37(3):313-318.
[25] Miller LW,Rogers JG. Evolution of left ventricular assist device therapy for advanced heart failure:a review[J]. JAMA Cardiol,2018,3(7):650-658.
[26] Lampert BC,Eckert C,Weaver S,et al. Blood pressure control in continuous flow left ventricular assist devices: efficacy and impact on adverse events[J]. Ann Thorac Surg,2014,97(1):139-146.
[27] Nassif ME,Larue SJ,Raymer DS,et al. Relationship between anticoagulation intensity and thrombotic or bleeding outcomes among outpatients with continuous-flow left ventricular assist devices[J]. Circ Heart Fail,2016,9(5):e002680.
[28] Gurvits GE,Fradkov E. Bleeding with the artificial heart:gastrointestinal hemorrhage in CF-LVAD patients[J]. World J Gastroenterol,2017,23(22):3945-3953.
[29] Baumwol J,Macdonald PS,Keogh AM,et al. Right heart failure and "failure to thrive" after left ventricular assist device:clinical predictors and outcomes[J]. J Heart Lung Transplant,2011,30(8):888-895.
[30] Unsworth B,Casula RP,Kyriacou AA,et al. The right ventricular annular velocity reduction caused by coronary artery bypass graft surgery occurs at the moment of pericardial incision[J]. Am Heart J,2010,159(2):314-322.
[31] Topkara VK,Kondareddy S,Malik F,et al. Infectious complications in patients with left ventricular assist device:etiology and outcomes in the continuous-flow era[J]. Ann Thorac Surg,2010,90(4):1270-1277.
[32] Gustafsson F,Rogers JG. Left ventricular assist device therapy in advanced heart failure:patient selection and outcomes[J]. Eur J Heart Fail,2017,19(5):595-602.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(9):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(9):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(9):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(9):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(9):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(9):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(9):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(9):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]